Regulations

May 28, 2020| Posted in: News, Regulations, Treatment

FDA Approves Drug to Treat Malaria

The  U.S. Food and Drug Administration (FDA) has…
May 25, 2020| Posted in: Cancers, News, Regulations, Treatment

FDA Approves New First-line Therapy for Rare Lung Cancer

The U.S. Food and Drug Administration (FDA) has…
May 19, 2020| Posted in: Cancers, Gastrointestinal Diseases, News, Regulations, Treatment

FDA Approves New Treatment for 4th-Line Treatment for GIST

The U.S. Food and Drug Administration (FDA) has…
May 18, 2020| Posted in: Cancers, News, Regulations, Skin Conditions, Treatment

FDA Approves New Drug for Kaposi Sarcoma

The U.S. Food and Drug Administration (FDA) has…
May 9, 2020| Posted in: Cancers, News, Regulations, Treatment

FDA Approves One Drug for Three Rare Cancer Subtypes

The  U.S. Food and Drug Administration (FDA) has…
Apr 21, 2020| Posted in: Cancers, Drug Development, News, Regulations, Treatment

FDA Approves Pemigatinib to Treat Cholangiocarcinoma

The  U.S. Food and Drug Administration has approved…

CME Program: Mucopolysaccharidoses (MPSs) Highlights from WORLDSymposium 2020

Barbara K. Burton, MD highlights the latest information about MPSs from WORLDSymposium and provides expert analysis of its clinical relevance for members of the care team in order to help them care for patients with these rare diseases.

WHIM Syndrome Learning Center

WHIM syndrome is a rare, congenital primary immunodeficiency disorder associated with severe neutropenia that affects all ages. However, due to the heterogeneous presentation of the disease, coupled with lack of awareness of the condition, the diagnosis may be delayed, sometimes even into adulthood.

CME Program: Gaucher Disease Highlights from WORLDSymposium 2020

Neal Weinreb, MD, FACP highlights the latest information about Gaucher disease from WORLDSymposium and provides expert analysis of its clinical relevance to help health care providers better care for patients with this rare disease.

CME Program: Fabry Disease Highlights from WORLDSymposium 2020

Ozlem Goker-Alpan, MD highlights the latest Fabry disease information from the WORLDSymposium and provides expert analysis of its clinical relevance for members of the care team in order to help them care for patients with this rare disease.

Tenosynovial Giant Cell Tumor (TGCT)

Tenosynovial giant cell tumor (TGCT) is a non-malignant tumor involving the joint synovium, bursae, and tendon sheath. These rare tumors are sometimes referred to as giant cell tumor of the tendon sheath (GCT-TS) and/or pigmented villonodular synovitis (PVNS).

CME Program: Managing Individuals With Eosinophilic Granulomatosis with Polyangiitis (EGPA)

Michael E. Wechsler, MD, MMSc provides an overview of Eosinophilic Granulomatosis with Polyangiitis (EGPA) – including how to shorten individuals’ diagnostic journey and the time till they access effective therapy – through these brief courses that are certified for CME credit.

TTR Amyloidosis CME Program

Morie A Gertz, MD, MACP provides an overview of TTR Amyloidosis – including how to shorten individuals’ diagnostic journey and the time till they access treatment which might improve their quality of life or even prevent disease progression – through these brief courses that are certified for CME credit.

Spinal Muscular Atrophy CME Program

Nancy L. Kuntz, MD, FAAN discusses diagnosing and managing people with spinal muscular atrophy through these brief courses that are certified for CME and CNEcredit.

Rare Disease Clinical Trials CME Program

Learn about clinical trials and rare diseases through these brief courses that are certified for CME and CNE credit.
  • Heather Lau, MD, MS, NYU School of Medicine, New York, NY
  • Morie A Gertz, MD, Mayo Clinic, Rochester, MN
  • Timothy Craig, DO, Penn State University, Hershey, PA
  • Eric T. Wong, MD, Harvard Medical School, Boston, MA

Disease Categories

Topics

  • Sign up
Lost your password? Please enter your username or email address. You will receive a link to create a new password via email.
We do not share your personal details with anyone.